Shots:

• The company has completed agreements with all six sites for its P-II (NCT06359379) study of Ropidoxuridine to treat glioblastoma. The company expects the study to be completed in 18-24mos.
• The P-II study has started enrolling patients (n=40) into two equal groups (960mg/day & 1,200 mg/day) to determine the optimal dose with aggressive, IDH wild-type, methylation-negative glioblastomas, 14 additional patients will be included at the optimal dosage to evaluate survival EP vs historical controls. Currently, radiation therapy is the SoC for this group, but studies show that more than half of these patients live for less than 12mos. post-diagnosis.
• Ropidoxuridine (IPdR) is a radiation sensitizer intended for use in combination with RT to treat glioblastoma.

Ref: Shuttle Pharmaceuticals | Image: Shuttle Pharmaceuticals

Related News:- Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com